Please ensure Javascript is enabled for purposes of website accessibility
Pfizer Says COVID-19 Vaccine Is Looking 90% Effective
gvw_ap_news
By Associated Press
Published 3 years ago on
November 9, 2020

Share

Pfizer said Monday that an early peek at the data on its coronavirus vaccine suggests the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration.

The announcement, less than a week after an election that was seen as a referendum on President Donald Trump’s handling of the crisis, was a rare and major piece of encouraging news lately in the battle against the scourge that has killed more than 1.2 million people worldwide, including almost a quarter-million in the United States alone. Confirmed cases in the U.S. were expected to eclipse 10 million on Monday, the highest in the world.

“We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.”

Dr. Anthony Fauci, the government’s top-infectious disease expert, said the results suggesting 90% effectiveness are “just extraordinary,” adding: “Not very many people expected it would be as high as that.”

“It’s going to have a major impact on everything we do with respect to COVID,” Fauci said.

Pharmaceutical companies and various countries are in a global race to develop a vaccine against the virus. Fauci said that the Pfizer vaccine and virtually all others in testing target the spike protein the coronavirus uses to infect cells, so the results validate that approach.

Monday’s announcement doesn’t mean for certain that a vaccine is imminent: This interim analysis, from an independent data monitoring board, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the U.S. and five other countries. Some participants got the vaccine, while others got dummy shots.

Whenever Any Vaccine Arrives, Initial Supplies Will Be Scarce and Rationed

Pfizer Inc. did not provide any more details about those infections and cautioned that the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual.

“We need to see the data, but this is extremely promising,” said Dr. Jesse Goodman of Georgetown University, former chief of the FDA’s vaccine division. He ticked off many questions still to be answered, including how long the vaccine’s effects last and whether it protects older people as well as younger ones.

Whenever any vaccine arrives, initial supplies will be scarce and rationed, with priority likely to be given to health care workers and others on the front lines. Pfizer has estimated that 50 million doses of its vaccine could be available globally by the end of 2020, which could cover 25 million people, since it is given in two doses.

Global markets, already buoyed by the victory of President-elect Joe Biden, exploded on the news from Pfizer. Major markets in Europe, where infections have soared, were up 5%. In the U.S., the S%P 500 surged 3.7% after the opening bell, and the Dow Jones Industrial Average was up more than 1,300 points.

Trump, who had suggested during the presidential campaign that a vaccine could be ready by Election Day, tweeted on Monday: “STOCK MARKET UP BIG, VACCINE COMING SOON. REPORT 90% EFFECTIVE. SUCH GREAT NEWS!”

The timing is likely to feed unsubstantiated suspicions from Trump supporters that the pharmaceutical industry was withholding the news until after the election. Donald Trump Jr. tweeted: “The timing of this is pretty amazing. Nothing nefarious about the timing of this at all right?”

Pfizer Chairman and CEO Albert Bourla said on CNBC that the election was always an artificial deadline and that the data was going to be ready when it was ready. The independent data monitors met on Sunday, analyzing the COVID-19 test results so far and notifying Pfizer.

“I am very happy,” Bourla said, “but at the same time, sometimes I have tears in my eyes when I realize that this is the end of nine months, day-and-night work of so many people and how many people, billions, invested hopes on this.”

FILE – In this Monday, Nov. 23, 2015, file photo, the Pfizer logo is displayed at world headquarters in New York. On Monday, Nov. 9, 2020, Pfizer said an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19. (AP Photo/Mark Lennihan, File)

Because the Study Hasn’t Ended, Gruber Couldn’t Say How Many in Each Group Had Infections

He added: “I never thought it would be 90%.”

Earlier this year, Fauci said he would be happy with a COVID-19 vaccine that was 60% effective. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective and require yearly shots.

Pfizer opted not to join the Trump administration’s Operation Warp Speed, which helped a half-dozen drugmakers accelerate their vaccine testing and helped fund the work. Instead, Pfizer funded all its testing and manufacturing costs itself. The company said it has invested billions of dollars.

The coronavirus shots, made by Pfizer and its German partner BioNTech, are among 10 possible vaccine candidates in late-stage testing around the world — four of them so far in huge studies in the U.S. Another U.S. company, Moderna Inc., also has said it hopes to be able to file an application with the FDA later this month.

Volunteers in the final-stage studies, and the researchers, don’t know who received the real vaccine or a dummy shot. But a week after their second required dose, Pfizer’s study began counting the number who developed COVID-19 symptoms and were confirmed to have the coronavirus.

Because the study hasn’t ended, Gruber couldn’t say how many in each group had infections. But the math suggests that almost all the infections counted so far had to have occurred in people who got the dummy shots.

Pfizer doesn’t plan to stop its study until it records 164 infections among all the volunteers, a number that the FDA has agreed is enough to tell how well the vaccine is working. The agency has made clear that any vaccine must be at least 50% effective.

No participant so far has become severely ill, Gruber said. Nor could he provide a breakdown of how many of the infections had occurred in older people, who are at highest risk from COVID-19.

Participants were tested only if they developed symptoms, leaving unanswered whether vaccinated people could get infected but show no symptoms and unknowingly spread the virus.

Because the Pandemic Is Still Raging, Manufacturers Hope to Seek Permission From Governments

Marylyn Addo, head of the tropical medicine unit at UKE hospital in Hamburg, Germany, said the interim results were “an interesting first signal,” but questions remain.

Public Citizen, the consumer advocacy group, called the release of the preliminary and incomplete data “bad science” and said that any enthusiasm for the results “must be tempered” until they are reviewed by the FDA and its independent experts.

“Crucial information absent from the companies’ announcement is any evidence that the vaccine prevents serious COVID-19 cases or reduces hospitalizations and deaths due to the disease,” the organization said.

FDA has told companies they must track half their participants for side effects for at least two months, the time period when problems typically crop up. Pfizer expects to reach that milestone later this month.

Because the pandemic is still raging, manufacturers hope to seek permission from governments around the world for emergency use of their vaccines while additional testing continues — allowing them to get to market faster than normal but raising concerns about how much scientists will know about the shots.

The FDA’s scientific advisers last month said they worry that allowing emergency use of a COVID-19 vaccine could damage confidence in the shots. Those advisers said it’s critical these massive studies are allowed to run to completion.

RELATED TOPICS:

DON'T MISS

Unlocking the Secrets to Fresno State’s Superb Baseball Season

DON'T MISS

‘This Is How to Improve Reading Proficiency. We Just Have Execute It’: FUSD Board President

DON'T MISS

Does Dyer Support (or Endorse) Bredefeld for Supervisor?

DON'T MISS

Get a 3D First Look at Merced’s High-Speed Rail Station Design

DON'T MISS

California Court to Decide on Transgender Ballot Measure Wording

DON'T MISS

Rare House Vote Sees Ukraine, Israel Aid Advance as Democrats Join Republicans

DON'T MISS

Full Jury and 6 Alternates Seated in Trump’s Hush Money Trial

DON'T MISS

Wired Wednesday: How High Will the Price of Gold & Silver Go?

DON'T MISS

How 4/20 Grew From Humble Roots to Marijuana’s High Holiday

DON'T MISS

Taylor Swift Drops 15 New Songs on Double Album, ‘The Tortured Poets Department: The Anthology’

UP NEXT

Full Jury and 6 Alternates Seated in Trump’s Hush Money Trial

UP NEXT

Barbara Corcoran: 1% Interest Rate Drop Will Send Housing Prices ‘Through the Roof’

UP NEXT

Juror Dismissed From Trump Hush Money Trial. Prosecutors Seek to Hold Former President in Contempt

UP NEXT

Biden Backs House’s Aid Package for Ukraine, Israel While Speaker Johnson Battles to Retain Position

UP NEXT

Myanmar’s Ousted Leader Suu Kyi Moved From Prison to House Arrest Due to Heat, Military Says

UP NEXT

NPR Editor Suspended Over Claims of Network’s ‘Progressive Worldview’

UP NEXT

Wall Street’s Mixed Trading Day

UP NEXT

New Recruiting Programs Put Army, Air Force on Track to Meet Enlistment Goals. Navy Will Fall Short

UP NEXT

Justice Thomas Misses Supreme Court Session Monday With No Explanation

UP NEXT

‘Civil War’ Declares Victory at the Box Office, Toppling ‘Godzilla X Kong’

Get a 3D First Look at Merced’s High-Speed Rail Station Design

2 hours ago

California Court to Decide on Transgender Ballot Measure Wording

2 hours ago

Rare House Vote Sees Ukraine, Israel Aid Advance as Democrats Join Republicans

4 hours ago

Full Jury and 6 Alternates Seated in Trump’s Hush Money Trial

4 hours ago

Wired Wednesday: How High Will the Price of Gold & Silver Go?

Video /

5 hours ago

How 4/20 Grew From Humble Roots to Marijuana’s High Holiday

5 hours ago

Taylor Swift Drops 15 New Songs on Double Album, ‘The Tortured Poets Department: The Anthology’

6 hours ago

Lamborghini’s Race Evolution: From Tractors to the Track

6 hours ago

Biden Administration Restricts Oil and Gas Leasing in 13 Million Acres of Alaska’s Petroleum Reserve

6 hours ago

Logan Webb’s Seven Dominant Innings Help Giants Blank Diamondbacks

6 hours ago

Unlocking the Secrets to Fresno State’s Superb Baseball Season

So, how has the Fresno State baseball team positioned itself atop the Mountain West Conference? San Jose State at Fresno State Friday: 6:05...

10 mins ago

10 mins ago

Unlocking the Secrets to Fresno State’s Superb Baseball Season

23 mins ago

‘This Is How to Improve Reading Proficiency. We Just Have Execute It’: FUSD Board President

54 mins ago

Does Dyer Support (or Endorse) Bredefeld for Supervisor?

2 hours ago

Get a 3D First Look at Merced’s High-Speed Rail Station Design

2 hours ago

California Court to Decide on Transgender Ballot Measure Wording

4 hours ago

Rare House Vote Sees Ukraine, Israel Aid Advance as Democrats Join Republicans

4 hours ago

Full Jury and 6 Alternates Seated in Trump’s Hush Money Trial

Video /
5 hours ago

Wired Wednesday: How High Will the Price of Gold & Silver Go?

MENU

CONNECT WITH US

Search

Send this to a friend